A stalwart in laboratory and clinic
Gary V. Desir, MD, has served the School of Medicine with distinction as a researcher, clinician, educator, and administrator. His discovery and further investigation of the flavoprotein renalase are milestones in the understanding of renal and cardiovascular function.Source: Medicine@Yale
Yale Study: Minority Breast Cancer Patients Less Likely To Have Genetic Test
A genetic test that helps doctors determine how best to treat breast cancer—and whether chemotherapy is likely to help—is significantly more likely to be administered to white women than blacks or Hispanics, a Yale study has found.Source: Connecticut Health I-Team
Automatic Palliative Care Consult for Patients with Advanced Cancers leads to Improved Outcomes
A study published Friday in the American Society of Clinical Oncology’s (ASCO) Journal of Oncology Practice is the first to demonstrate that increased palliative care consultations for patients with advanced cancers is associated with substantial impact on 30-day readmission, administration of chemotherapy following discharge, hospice referral, and use of support services following discharge.
Racial Disparities in Genetic Testing of Women With Breast Cancer
MedicalResearch.com Interview with: Cary P. Gross, MD Section of General Internal Medicine Yale University School of Medicine New Haven, CT MedicalResearch.com: What is the background for this study? What are the main findings? Response: Prior work has demonstrated racial and socioeconomic disparities in breast cancer diagnosis, treatment, and outcomes. As the oncology field has progressed over the past decade, the use of genetic testing to guide treatment decisions is one of the most exciting new developments.Source: Medical Research
Yale Study Published in JNCCN Uncovers Racial Disparities in Treatment of Women with Breast Cancer
In a simple definition, cancer is a disease of the cells, which is caused by gene mutations. For a proportion of patients, including women with hormone receptor positive (HR+) breast cancer, gene expression profiling has a substantial impact on treatment decision-making by determining which patients might—or might not—respond to particular treatment options.
When cancer treatments do more harm than good
To be sure, patients deserve prompt access to effective, cutting-edge treatments. But what if a treatment turns out to do more harm than good? This is why we need to double down on our efforts to evaluate new treatments in the real world. We need more evidence, not less. The FDA shouldn’t shy away from requiring thorough evaluation of new drugs. The same level of enthusiasm and funding that goes into developing new treatments should be invested in testing whether they are safe and effective in patients outside of the initial small trials. Undertested drugs with unclear safety profiles and efficacy should not be given to broad swaths of the population.Source: Washington Post
Innovative breast reconstruction: An amazing result enhances self-esteem
For Lauren Raccio, breast cancer treatment at Yale Medicine started because her life was in danger. The journey involved a remarkable form of breast reconstruction called ‘DIEP flap.’ The result is a breast that looks and feels natural, and is more resilient to radiation after surgery.Source: Yale Medicine
New Haven cancer doctors working to draw people of color into clinical trials
Minorities make up about 10 percent to 12 percent of the participants in clinical trials at Smilow, which recruits participants from across Connecticut, said Dr. Roy Herbst, chief of medical oncology. But, given that New Haven is about two-thirds black or Hispanic, both Herbst and Silber would like to increase the number of minorities who can benefit from new drugs. “We want to bring the best care to all people; we want to bring access to all people,” said Herbst, who said he’d like to at least double the percentage of minorities in Smilow’s trials of cancer drugs.Source: New Haven Register
Reducing Radiation Successfully Treats HPV-Positive Oropharynx Cancers and Minimizes Side Effects
Human papillomavirus-positive oropharynx cancers (cancers of the tonsils and back of the throat) are on rise. After radiation treatment, patients experience severe, lifelong swallowing, eating, and nutritional issues. However, new clinical trial research shows reducing radiation for some patients with HPV-associated oropharyngeal squamous cell carcinomas can maintain high cure rates while sparing some of these late toxicities.
Clinical Pathways Through Quality Metrics: ASCO’s Quality Oncology Practice Initiative
In order to better understand how QOPI can improve patient care and aid in the implementation of clinical pathways, Journal of Clinical Pathways spoke with Anne C Chiang, MD, PhD, assistant professor of medicine (medical oncology) at Yale School of Medicine, and chief network officer and deputy chief medical officer of Smilow Cancer Network (New Haven, CT). In her roles with Smilow Cancer Network, Dr Chiang manages operations for a conglomerated multitude of affiliated oncology practices providing care to patients throughout the state of Connecticut. In her role as chair of ASCO’s Quality of Care Committee, Dr Chiang has written and presented extensively on QOPI’s utility in strengthening value-based cancer care.Source: Journal of Clinical Pathways
Alternative Option to Intensive Chemotherapy for Patients with relapsed/refractory Acute Myeloid Leukemia (AML)
A Yale Cancer Center team has evaluated the use of hypomethylating agents in patients suffering from Acute Myeloid Leukemia (AML) who were resistant to treatment with intensive chemotherapy. Study results revealed that the complete response rate to hypomethylating agents (HMAs) in patients with refractory or relapsed AML (RR-AML) is about 16%. Among patients who achieved a complete response, the survival was significantly improved compared to those who did not respond. The findings were presented December 5, 2016 at the American Society of Hematology (ASH) meeting in San Diego.
Yale Developing Text System To Remind Breast Cancer Patients To Take Medication
Yale researchers hope a text messaging program they are developing will improve outcomes for certain breast cancer patients by reminding them to take their medication. Breast Cancer Endocrine Therapy Adherence (BETA) Text is designed for patients who have hormone-sensitive breast cancer, which typically is treated with five to 10 years of endocrine therapy in the form of a daily pill, said Dr. Sarah Mougalian, developer of BETA Text at Smilow Cancer Hospital at Yale New Haven and assistant professor of medicine at Yale Cancer Center.Source: The Hartford Courant
Study finds differences in care for patients with low-risk prostate cancer based on institution and region
Men with low-risk prostate cancer have a variety of treatment options because of the relatively benign nature of their disease. Among many factors that influence treatment decisions, the type of cancer center a patient visits is a key one, according to a study led by Yale researchers.
Cancer Researchers Struggle To Persevere With Limited Funds
Dr. Roy Herbst, chief of medical oncology at Yale's Smilow Cancer Hospital, is running one site of a lung cancer clinical trial that fits exactly into the goals of the Obama administrations' new cancer moonshot.Source: The Hartford Courant